, Tracking Stock Market Picks
Enter Symbol:
Rating: MNTA

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) upgraded to Hold by Maxim Group

Friday,  Jan 8, 2016  2:25 PM ET by Lynn Gilbert

Maxim Group upgraded Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) to Hold. Previously, Maxim
Group rated Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) to Sell with price target $7 on 01/23/2015, when the stock price was valued at $10.60.

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy